ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)

被引：2
|
作者：
Ibrahim, Nuhad
Kim, Sung-Bae
Lin, Nancy
Awada, Ahmad
Gil, Eva Ciruelos
Tonini, Giulia
Vallespir, Bartomeu Piza
Theall, Kathy Puvana
Hamilton, Erika
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2-aBC) who had rapid progression (RP) in acelERA BC
    Martin Jimenez, M.
    Hilz, S.
    Collier, A.
    Chibly, A.
    Sohn, J.
    Bardia, A.
    Lim, E.
    Mac Gregor, M. Chavez
    Martinalbo, J.
    Perez-Moreno, P. D.
    Moore, H. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S356 - S357
  • [42] Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
    Vidal, Maria
    Falato, Claudette
    Pascual, Tomas
    Sanchez-Bayona, Rodrigo
    Munoz-Mateu, Montserrat
    Cebrecos, Isaac
    Gonzalez-Farre, Xavier
    Cortadellas, Tomas
    Vila, Mireia Margeli
    Luna, Miguel A.
    Siso, Christian
    Amillano, Kepa
    Galvan, Patricia
    Bergamino, Milana A.
    Ferrero-Cafiero, Juan M.
    Salvador, Fernando
    Espinosa Guerrero, Alejandra
    Pare, Laia
    Sanfeliu, Esther
    Prat, Aleix
    Bellet, Meritxell
    CLINICAL CANCER RESEARCH, 2025, 31 (07) : 1223 - 1232
  • [43] SOLTI-1802 ONAWA trial: A window of opportunity trial of onapristone (ONA) in postmenopausal women with estrogen and progesterone receptor-positive/HER2-negative (ER+/PgR+/HER2-) early breast cancer (EBC)
    Bellet, M.
    Morales Murillo, S.
    Gasol Cudos, A.
    Amillano, K.
    Chic, N.
    Gonzalez-Farre, X.
    Villagrasa, P.
    Ferrero-Cafiero, J. M.
    Pascual, T.
    Prat, A.
    Lange, C.
    Saura Manich, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S36 - S36
  • [44] Analysis of estrogen receptor positive (ER+), progesterone receptor negative (PR-) phenotype and HER2 status in breast cancer (BC) patients
    Mitrovic, Slobodanka
    Stankovic, Vesna
    Azanjac, Goran
    Ninkovic, Srdan
    VIRCHOWS ARCHIV, 2007, 451 (02) : 299 - 299
  • [45] An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2-) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC
    Tripathy, D.
    Moisa, C.
    Gluck, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 223 - 223
  • [46] A phase 1/2 dose escalation and expansion study of OP-1250 in adults with advanced and/or metastatic hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer
    Alemany, Carlos
    Patel, Manish
    Mitri, Zahi
    Sparano, Joseph
    Borges, Virginia
    Makower, Della
    Klein, Pam
    Lawrence, Julia
    Le, Trinh
    Zujewski, Jo Anne
    Harmilton, Erika
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [47] Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
    Hurvitz, Sara A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso-Romero, Jose Luis
    Vasiliev, Aleksandr
    Adamchuk, Hryhoriy
    Salgado, Marcelo
    Yardley, Denise A.
    Berzoy, Oleksandr
    Zamora-Aunon, Pilar
    Chan, David
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    LANCET ONCOLOGY, 2023, 24 (09): : 1029 - 1041
  • [48] Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL
    Llombart-Cussac, Antonio
    Gligorov, Joseph
    Di Cosimo, Serena
    Albacar, Cinta
    Cortez, Patricia
    Duenas, Eduardo Martinez-De
    Lopez, Ana
    Caranana, Vicente
    Medioni, Jacques
    Cavanna, Luigi
    Cazzaniga, Marina Elena
    Braga, Sofia
    Coelho, Passos
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    CANCER RESEARCH, 2022, 82 (04)
  • [49] Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician's choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2-aBC)
    Collier, Ann
    Mac Gregor, Mariana Chavez
    Hilz, Stephanie
    Bardia, Aditya
    Sohn, Joohyuk
    Martin, Miguel
    Lim, Elgene
    Martinalbo, Jorge
    Perez-Moreno, Pablo Diego
    Moore, Heather M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation
    Goetz, Matthew P.
    Wander, Seth Andrew
    Bachelot, Thomas
    Batist, Gerald
    Cortes, Javier
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    De Nonneville, Alexandre
    Gal-Yam, Einav Nili
    Jhaveri, Komal L.
    Ma, Cynthia X.
    Parsons, Heather Anne
    Rugo, Hope S.
    Sammons, Sarah L.
    Stover, Daniel G.
    Twelves, Chris
    Bardia, Aditya
    Plourde, Paul V.
    Portman, David Jay
    Damodaran, Senthil
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345